Showing results (101-110 of 171) with videos related to
Sort By:
Pageof 18
Cancers|April 29, 2020
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsStephan Rheinheimer, Claus-Peter Heussel, Philipp Mayer, et al.Translational Lung Cancer Research|April 23, 2021
Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinibJingjing Li, Bin Zhang, Yu Zhang, et al.Translational Lung Cancer Research|December 15, 2022
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approachLaura V Klotz, Hans Hoffmann, Rajiv Shah, et al.The Journal of Pathology. Clinical Research|January 29, 2024
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitorsMichael Menzel, Martina Kirchner, Klaus Kluck, et al.Cold Spring Harbor Molecular Case Studies|November 23, 2019
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK-rearranged lung cancerSteffen Dietz, Petros Christopoulos, Lisa Gu, et al.Clinical and Translational Radiation Oncology|December 9, 2024
Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factorsAnna Krämer, Laura Hahnemann, Fabian Schunn, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2015
A novel thymoma-associated immunodeficiency with increased naive T cells and reduced CD247 expressionPetros Christopoulos, Elaine P Dopfer, Miroslav Malkovsky, et al.Journal of Comparative Effectiveness Research|January 21, 2025
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapyMichael Thomas, Petros Christopoulos, Wade T Iams, et al.Frontiers in Oncology|December 18, 2020
Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration RatesTanja Eichkorn, Farastuk Bozorgmehr, Sebastian Regnery, et al.Lung Cancer (Amsterdam, Netherlands)|August 16, 2023
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implicationsHuriye Seker-Cin, Timothy Kwang Yong Tay, Daniel Kazdal, et al.Pageof 18